Canaccord Genuity Maintains Buy on GeneDx Holdings, Raises Price Target to $90

Benzinga Newsdesk www.benzinga.com Positive 72.4%

Neg 0% Neu 0% Pos 72.4%

Canaccord Genuity analyst Kyle Mikson maintains GeneDx Holdings (NASDAQ:WGS) with a Buy and raises the price target from $75 to $90.